These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293 [Abstract] [Full Text] [Related]
9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER. Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613 [Abstract] [Full Text] [Related]
10. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Sufan RI, Jewett MA, Ohh M. Am J Physiol Renal Physiol; 2004 Jul 01; 287(1):F1-6. PubMed ID: 15180922 [Abstract] [Full Text] [Related]
15. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T. Oncol Rep; 2005 Jun 01; 13(6):1033-41. PubMed ID: 15870918 [Abstract] [Full Text] [Related]
16. The HIF and other quandaries in VHL disease. Tarade D, Ohh M. Oncogene; 2018 Jan 11; 37(2):139-147. PubMed ID: 28925400 [Abstract] [Full Text] [Related]